CAS NO: | 20283-92-5 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Rosmarinic acid is a widespread phenolic ester compound in theplants. Rosmarinic acid inhibitsMAO-A,MAO-BandCOMTenzymes withIC50s of 50.1, 184.6 and 26.7 μM, respectively. | ||||||||||||||||
IC50& Target | IC50: 50.1 μM (MAO-A), 184.6 μM (MAO-B), 26.7 μM (COMT)[1] | ||||||||||||||||
体外研究 (In Vitro) | Rosmarinic acid (RA) shows an in vitro multifunctional profile characterized by antioxidant effects, and monoamine oxidases (MAO-A and MAO-B) and catechol-O-methyl transferase (COMT) inhibition. Rosmarinic acid shows antioxidant effects against hydroxyl (HO(o)) and nitric oxide (NO) radicals (IC50of 29.4 and 140 μM, respectively), and inhibition of lipid peroxidation (IC50of 19.6 μM)[1]. Rosmarinic acid (RA) exerts a significant cytoprotective effect by scavenging intracellular ROS induced by UVB. In H2O2-treated cells, 2.5 μM Rosmarinic acid scavenges 60% of intracellular ROS compared to 77% of intracellular ROS scavenging effect in N-acetyl-L-cysteine (NAC)[2]. | ||||||||||||||||
体内研究 (In Vivo) | Rosmarinic acid (RA) is a widespread phenolic ester compound in the plants, particularly those in the Labiatae family of herbs, such asRosmarinus officinali,Salvia miltiorrhiza, andPrunella vulgaris. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. In the DSS-induced colitis model, Treatment with Rosmarinic acid (30, 60 mg/kg, p.o.) markedly attenuates the production of cytokines[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 360.31 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C18H16O8 | ||||||||||||||||
CAS 号 | 20283-92-5 | ||||||||||||||||
中文名称 | 迷迭香酸;酪萨维;罗丹酚酸;肉桂醇甙 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 62.5 mg/mL(173.46 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|